EUR 1.78
(0.79%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 1.00 EUR | 0.0% |
2022 | - EUR | 0.0% |
2021 | - EUR | 0.0% |
2020 | - EUR | 0.0% |
2019 | - EUR | 100.0% |
2018 | -91 Thousand EUR | -97.83% |
2017 | -46 Thousand EUR | 72.29% |
2016 | -166 Thousand EUR | -32.8% |
2015 | -125 Thousand EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | -100.0% |
2012 | 18 Thousand EUR | 0.0% |
2011 | 18 Thousand EUR | -57.14% |
2010 | 42 Thousand EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 368 Thousand EUR | 0.0% |
2023 Q4 | 1.00 EUR | 0.0% |
2023 Q2 | - EUR | 0.0% |
2023 FY | 1.00 EUR | 0.0% |
2022 Q2 | - EUR | 0.0% |
2022 FY | - EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2021 FY | - EUR | 0.0% |
2021 Q2 | 1.00 EUR | 0.0% |
2021 Q4 | - EUR | 0.0% |
2020 Q4 | - EUR | 0.0% |
2020 FY | - EUR | 0.0% |
2020 Q2 | - EUR | 0.0% |
2019 FY | - EUR | 100.0% |
2019 Q4 | - EUR | 0.0% |
2019 Q2 | - EUR | 0.0% |
2018 FY | -91 Thousand EUR | -97.83% |
2018 Q2 | - EUR | 0.0% |
2018 Q4 | - EUR | 0.0% |
2017 Q2 | - EUR | 0.0% |
2017 FY | -46 Thousand EUR | 72.29% |
2017 Q4 | - EUR | 0.0% |
2016 Q4 | - EUR | 0.0% |
2016 Q2 | 840.00 EUR | 0.0% |
2016 FY | -166 Thousand EUR | -32.8% |
2015 Q2 | - EUR | 0.0% |
2015 Q4 | - EUR | 0.0% |
2015 FY | -125 Thousand EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 FY | - EUR | -100.0% |
2012 FY | 18 Thousand EUR | 0.0% |
2011 FY | 18 Thousand EUR | -57.14% |
2010 FY | 42 Thousand EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Boiron SA | 96.76 Million EUR | 100.0% |
Laboratorios Farmaceuticos Rovi, S.A. | 337.96 Million EUR | 100.0% |
Vetoquinol SA | 103.53 Million EUR | 100.0% |
Valneva SE | 44.46 Million EUR | 100.0% |
AB Science S.A. | 336 Thousand EUR | 100.0% |
Nanobiotix S.A. | 200 Thousand EUR | 100.0% |
PHAXIAM Therapeutics S.A. | 671 Thousand EUR | 100.0% |
BioSenic S.A. | - EUR | -Infinity% |
ABIVAX Société Anonyme | 1.00 EUR | 0.0% |
Formycon AG | 467 Thousand EUR | 100.0% |